fda compounding semaglutide crackdown news today 2025 Report: must enforce rules on compounded GLP-1s FDA crackdown on off-brand Ozempic

PMID: 40563436 | doi:10.3390/biom15060796

Once you start taking a GLP-1 for type 2 diabetes, you'll start eating less

This leads to an increase in intracellular cyclic adenosine monophosphate ( cAMP ) levels

How the Three GLP-1 Medications Compare Mounjaros dual-action mechanism produces more dramatic weight loss and a higher rate of hair shedding

One user, who wanted to be known only as Amy, said she switched from an approved weight loss drug to Reta Pens because of price

Retatrutide (development code LY3437943) is an investigational once-weekly injectable weight loss medication developed by Eli Lilly and Company the same pharmaceutical company behind Mounjaro (tirzepatide) and the oral GLP-1 pill orforglipron (Foundayo)